top of page

Search

Richmond Times-Dispatch Article about NEXT Molecular Analytics

gmeyers14
Nov 12, 2015
1 min read

Bio Research Services

NEXT Molecular Analytics article in the business section of the Richmond Times-Dispatch.

Recent Posts

NEXT Scientist publishes paper: Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions

NEXT Scientist publishes paper: Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions

L-asparaginase chemotherapy is integral in the treatment of pediatric, adolescent, and young adult (AYA) patients with Acute Lymphoblastic Leukemia (ALL). Its incorporation, as part of a multi-agent c

L-asparaginase chemotherapy is integral in the treatment of pediatric, adolescent, and young adult (AYA) patients with Acute Lymphoblastic Leukemia (ALL). Its incorporation, as part of a multi-agent c

NEXT Scientists contribute to paper on pharmacogenomics of CYP450 genes

NEXT Scientists contribute to paper on pharmacogenomics of CYP450 genes

Comments

Featured Posts

Check back soon

Once posts are published, you’ll see them here.

Recent Posts

NEXT Scientist publishes paper: Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions

NEXT Scientist publishes paper: Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions

NEXT Scientist publishes paper: Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions

L-asparaginase chemotherapy is integral in the treatment of pediatric, adolescent, and young adult (AYA) patients with Acute Lymphoblastic Leukemia (ALL). Its incorporation, as part of a multi-agent c

L-asparaginase chemotherapy is integral in the treatment of pediatric, adolescent, and young adult (AYA) patients with Acute Lymphoblastic Leukemia (ALL). Its incorporation, as part of a multi-agent c

L-asparaginase chemotherapy is integral in the treatment of pediatric, adolescent, and young adult (AYA) patients with Acute Lymphoblastic Leukemia (ALL). Its incorporation, as part of a multi-agent c

NEXT Scientists contribute to paper on pharmacogenomics of CYP450 genes

CiRT Receives Clinical Approval from NYSHD CLEP

NEXT Molecular Analytics Receives Accreditation from the New York State Department of Health for its L-Asparaginase Enzyme Activity Assay Platform

Oxford BioDynamics announces US launch of its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) foroncology

Richmond Times-Dispatch Article about NEXT Molecular Analytics

NEXT to Present Keynote Presentation on Precision Medicine

NEXT BIO-RESEARCH SERVICES LLC BEGINS OPERATIONS

Archive

Search By Tags

Follow Us

bottom of page